Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer

[1]  R. Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128)) , 2008 .

[2]  G. Thomas,et al.  mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. , 2007, Trends in molecular medicine.

[3]  J. Castro,et al.  Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism , 2007, Oncogene.

[4]  W. Yung,et al.  Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo , 2007, Molecular Cancer Therapeutics.

[5]  A. Fukamizu,et al.  Insulin-like Growth Factor 1/Insulin Signaling Activates Androgen Signaling through Direct Interactions of Foxo1 with Androgen Receptor* , 2007, Journal of Biological Chemistry.

[6]  D. Clemmons.  Value of insulin-like growth factor system markers in the assessment of growth hormone status. , 2007, Endocrinology and metabolism clinics of North America.

[7]  E. Surmacz,et al.  Crosstalk between IGF signaling and steroid hormone receptors in breast cancer. , 2007, Current pharmaceutical design.

[8]  F. Giorgino,et al.  The IGF-I signaling pathway. , 2007, Current pharmaceutical design.

[9]  Y. León,et al.  Anti-apoptotic actions of insulin-like growth factors: lessons from development and implications in neoplastic cell transformation. , 2007, Current pharmaceutical design.

[10]  C. Nanni,et al.  Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor–Specific Inhibitor in Ewing's Sarcoma , 2007, Clinical Cancer Research.

[11]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[12]  P. Harari,et al.  Insulin-like growth factor-I receptor signaling blockade combined with radiation. , 2007, Cancer research.

[13]  Stephen F Kemp.  Mecasermin rinfabate. , 2007, Drugs of today.

[14]  J. Riedemann,et al.  IGF1R signalling and its inhibition. , 2006, Endocrine-related cancer.

[15]  G. Striker,et al.  Smoking induces glomerulosclerosis in aging estrogen-deficient mice through cross-talk between TGF-beta1 and IGF-I signaling pathways. , 2006, Journal of the American Society of Nephrology : JASN.

[16]  C. Dominici,et al.  Down-Regulation of Insulin-Like Growth Factor I Receptor Activity by NVP-AEW541 Has an Antitumor Effect on Neuroblastoma Cells In vitro and In vivo , 2006, Clinical Cancer Research.

[17]  J. Avruch,et al.  Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase , 2006, Oncogene.

[18]  T. Shiomi,et al.  ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. , 2006, Cancer research.

[19]  L. Poellinger,et al.  Hypoxia-Inducible Factor-1α and Hypoxia-Inducible Factor-2α Are Expressed in Kaposi Sarcoma and Modulated by Insulin-like Growth Factor-I , 2006, Clinical Cancer Research.

[20]  D. Ludwig,et al.  Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis , 2006, Cancer Immunology, Immunotherapy.

[21]  A. Martins,et al.  Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing Tumor , 2006, Clinical Cancer Research.

[22]  O. Gavrilova,et al.  Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. , 2006, Endocrinology.

[23]  S. Schow,et al.  Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth , 2006, Molecular Cancer Therapeutics.

[24]  S. Grundy,et al.  Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. , 2006, Journal of the American College of Cardiology.

[25]  Y. Kariya,et al.  Insulin-like growth factor-1 induces migration and expression of laminin-5 in cultured human corneal epithelial cells. , 2006, Investigative ophthalmology & visual science.

[26]  O. Larsson,et al.  The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  D. Yee,et al.  Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. , 2006, Cancer research.

[28]  R. Rosenfeld.  Molecular Mechanisms of IGF-I Deficiency , 2006, Hormone Research in Paediatrics.

[29]  M. Pollak,et al.  Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. , 2006, Gynecologic oncology.

[30]  D. Yee,et al.  Targeting insulin-like growth factor pathways , 2006, British Journal of Cancer.

[31]  O. Larsson,et al.  Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. , 2006, Blood.

[32]  M. Messi,et al.  Motor neurone targeting of IGF‐1 prevents specific force decline in ageing mouse muscle , 2006, The Journal of physiology.

[33]  Hisayuki Yokoyama,et al.  Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. , 2006, The Tohoku journal of experimental medicine.

[34]  T. Shiomi,et al.  ADAM 28 Is Overexpressed in Human Breast Carcinomas : Implications for Carcinoma Cell Proliferation through Cleavage of Insulin-like Growth Factor Binding Protein-3 , 2006 .

[35]  C. Conover,et al.  In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. , 2006, Cancer research.

[36]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[37]  Chiehying Y Chang,et al.  Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. , 2005, Journal of medicinal chemistry.

[38]  A. Ochiai,et al.  Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. , 2005, Biochemical and biophysical research communications.

[39]  A. Rogol,et al.  Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. , 2005, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[40]  D. Housman,et al.  Microdeletion and IGF2 loss of imprinting in a cascade causing Beckwith-Wiedemann syndrome with Wilms' tumor , 2005, Nature Genetics.

[41]  W. R. Bishop,et al.  Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody , 2005, Molecular Cancer Therapeutics.

[42]  L. Maile,et al.  Role of SHPS-1 in the regulation of insulin-like growth factor I-stimulated Shc and mitogen-activated protein kinase activation in vascular smooth muscle cells. , 2005, Molecular biology of the cell.

[43]  D. Hicklin,et al.  A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity* , 2005, Journal of Biological Chemistry.

[44]  H. Yi,et al.  Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. , 2005, Biochemical and biophysical research communications.

[45]  M. Ranke.  Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance , 2005, Trends in Endocrinology & Metabolism.

[46]  E. Van Obberghen,et al.  Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I. , 2005, Molecular endocrinology.

[47]  K. Shitara,et al.  Blockade of Paracrine Supply of Insulin-Like Growth Factors Using Neutralizing Antibodies Suppresses the Liver Metastasis of Human Colorectal Cancers , 2005, Clinical Cancer Research.

[48]  Adrian V. Lee,et al.  Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. , 2005, Cancer research.

[49]  P. Lollini,et al.  Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. , 2005, Cancer research.

[50]  R. Vessella,et al.  In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors , 2005, Clinical Cancer Research.

[51]  M. Axelson,et al.  Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival , 2005, British Journal of Cancer.

[52]  Mark W Tengowski,et al.  Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871 , 2005, Clinical Cancer Research.

[53]  F. Hofmann,et al.  The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy , 2005, Clinical Cancer Research.

[54]  N. Rosenthal,et al.  Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. , 2005, The Journal of clinical investigation.

[55]  P. Pauwels,et al.  A recombinant humanized anti‐insulin‐like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor receptor therapy against human cancer xenografts , 2005, International journal of cancer.

[56]  C. Lang,et al.  Cytokine inhibition of JAK-STAT signaling: a new mechanism of growth hormone resistance , 2005, Pediatric Nephrology.

[57]  S. Shalet,et al.  The Insulin-Like Growth Factor I Generation Test in Adults , 2005, Hormone Research in Paediatrics.

[58]  E. Medico,et al.  IGF‐II Binding to Insulin Receptor Isoform A Induces a Partially Different Gene Expression Profile from Insulin Binding , 2004, Annals of the New York Academy of Sciences.

[59]  T. Pandita,et al.  Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. , 2004, Endocrinology.

[60]  P. Ye,et al.  Astrocyte‐specific overexpression of insulin‐like growth factor‐I promotes brain overgrowth and glial fibrillary acidic protein expression , 2004, Journal of neuroscience research.

[61]  J. Frystyk.  Free insulin-like growth factors -- measurements and relationships to growth hormone secretion and glucose homeostasis. , 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[62]  K. Ho,et al.  Estrogen regulation of growth hormone action. , 2004, Endocrine reviews.

[63]  D. Dunger,et al.  Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[64]  E. Fleck,et al.  Proprotein convertases regulate insulin-like growth factor 1-induced membrane-type 1 matrix metalloproteinase in VSMCs via endoproteolytic activation of the insulin-like growth factor-1 receptor. , 2004, Biochemical and biophysical research communications.

[65]  S. Meloche,et al.  Dual Regulation of MMP-2 Expression by the Type 1 Insulin-like Growth Factor Receptor , 2004, Journal of Biological Chemistry.

[66]  D. Fabbro,et al.  In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. , 2004, Cancer cell.

[67]  T. Libermann,et al.  Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. , 2004, Cancer cell.

[68]  P. Bohlen,et al.  Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody* , 2004, Journal of Biological Chemistry.

[69]  K. Yano,et al.  Matrix Metalloproteinase-7 Facilitates Insulin-Like Growth Factor Bioavailability through Its Proteinase Activity on Insulin-Like Growth Factor Binding Protein 3 , 2004, Cancer Research.

[70]  Freddie H. Fu,et al.  Recovery of Articular Cartilage Metabolism following Thermal Stress is Facilitated by IGF-1 and JNK Inhibitor , 2004, The American journal of sports medicine.

[71]  D. Yee,et al.  Insulin‐like growth factor (IGF)‐I rescues breast cancer cells from chemotherapy‐induced cell death – proliferative and anti‐apoptotic effects , 1999, Breast Cancer Research and Treatment.

[72]  M. Bouxsein,et al.  Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. , 2004, The Journal of clinical investigation.

[73]  Peter Bohlen,et al.  A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. , 2003, Cancer research.

[74]  J. Wallace,et al.  The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[75]  P. Froment,et al.  The Insulin-like Growth Factor Axis in Cell Cycle Progression , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[76]  D. Yee,et al.  Combined Effects of Tamoxifen and a Chimeric Humanized Single Chain Antibody against the Type I IGF Receptor on Breast Tumor Growth In vivo , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[77]  J. Ricort,et al.  Growth factor-specific regulation of insulin receptor substrate-1 expression in MCF-7 breast carcinoma cells: effects on the insulin-like growth factor signaling pathway. , 2003, Endocrinology.

[78]  D. Carbone,et al.  Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. , 2003, Cancer research.

[79]  E. Surmacz.  Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor , 2003, Oncogene.

[80]  L. Maile,et al.  Tyrosine Phosphorylation of the β3-Subunit of the αVβ3 Integrin Is Required for Membrane Association of the Tyrosine Phosphatase SHP-2 and Its Further Recruitment to the Insulin-Like Growth Factor I Receptor , 2003 .

[81]  S. Monti,et al.  Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. , 2003, Anticancer research.

[82]  E. K. Maloney,et al.  An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. , 2003, Cancer research.

[83]  Domenico Coppola,et al.  Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. , 2003, Human pathology.

[84]  O. Larsson,et al.  Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[85]  D. Trichopoulos,et al.  Endometrial Cancer and the IGF System: A Case-Control Study in Greece , 2003, Oncology.

[86]  A. Feinberg,et al.  Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk , 2003, Science.

[87]  Donglei Zhang,et al.  Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling , 2003, Oncogene.

[88]  D. Yee,et al.  A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. , 2003, Cancer research.

[89]  M. Spitz,et al.  Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. , 2003, The Journal of urology.

[90]  N. Deng,et al.  Insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells. , 2003, Oncology reports.

[91]  Li Mao,et al.  Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[92]  G. Baretton,et al.  Overexpression of the insulin‐like growth factor I receptor in human colon carcinomas , 2002, Cancer.

[93]  L. Ellis,et al.  Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells* , 2002, The Journal of Biological Chemistry.

[94]  T. Jørgensen,et al.  Heart Disease : A Population-Based Case-Control Study Low Serum Insulin-Like Growth Factor I Is Associated With Increased Risk of Ischemic , 2002 .

[95]  S. Vannucci,et al.  IGF‐I and microglia/macrophage proliferation in the ischemic mouse brain , 2002, Glia.

[96]  D. Clemmons,et al.  Increases in Free, Unbound Insulin-like Growth Factor I Enhance Insulin Responsiveness in Human Hepatoma G2 Cells in Culture* , 2002, The Journal of Biological Chemistry.

[97]  P. Geusens,et al.  Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. , 2002, The Journal of clinical endocrinology and metabolism.

[98]  L. Hennighausen,et al.  Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. , 2002, Cancer research.

[99]  Martine J Jager,et al.  Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. , 2002, Investigative ophthalmology & visual science.

[100]  N. Ling,et al.  Discovery of a series of nonpeptide small molecules that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins. , 2001, Journal of medicinal chemistry.

[101]  N. Probst-Hensch,et al.  IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai , 2001, British Journal of Cancer.

[102]  E. Baudin,et al.  Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. , 2001, Cancer research.

[103]  D. Yee,et al.  The IGF system and breast cancer. , 2001, Endocrine-related cancer.

[104]  N. Ling,et al.  Identification of a Nonpeptide Ligand That Releases Bioactive Insulin-like Growth Factor-I from Its Binding Protein Complex* , 2001, The Journal of Biological Chemistry.

[105]  G. Shulman,et al.  Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. , 2001, Genes & development.

[106]  D. Witte,et al.  Targeted overexpression of IGF-I in smooth muscle cells of transgenic mice enhances neointimal formation through increased proliferation and cell migration after intraarterial injury. , 2001, Endocrinology.

[107]  D. Andrews,et al.  Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  P. Brodt,et al.  The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis. , 2001, Surgical oncology clinics of North America.

[109]  P. Backeljauw,et al.  Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. , 2001, The Journal of clinical endocrinology and metabolism.

[110]  T. Quattrin,et al.  Improvement of HbA1c Without Increased Hypoglycemia in Adolescents and Young Adults with Type 1 Diabetes Mellitus Treated with Recombinant Human Insulin-like Growth Factor-I and Insulin , 2001, Journal of pediatric endocrinology & metabolism : JPEM.

[111]  A. Hofman,et al.  A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. , 2001, Diabetes.

[112]  K. Shitara,et al.  Therapeutic potential of chimeric anti-(ganglioside GD3) antibody KM871: antitumor activity in xenograft model of melanoma and effector function analysis , 2000, Cancer Immunology, Immunotherapy.

[113]  J. Jorcano,et al.  Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[114]  D. Krause,et al.  Regulation of survival signals from the insulin-like growth factor-I receptor. , 2000, Biochemical Society transactions.

[115]  A. Wu,et al.  Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth , 2000, Cancer Immunology, Immunotherapy.

[116]  D. Clemmons,et al.  Reduction in atherosclerotic lesion size in pigs by alphaVbeta3 inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signaling. , 1999, Circulation research.

[117]  D. Chinkes,et al.  Anabolic effects of insulin-like growth factor in combination with insulin-like growth factor binding protein-3 in severely burned adults. , 1999, The Journal of trauma.

[118]  J. Chrast,et al.  Angiotensin II stimulates gene expression of cardiac insulin-like growth factor I and its receptor through effects on blood pressure and food intake. , 1999, Hypertension.

[119]  T. Yeatman,et al.  Expression of insulin-like growth factor-1 receptor in human colorectal cancer. , 1999, Human pathology.

[120]  T. Peng,et al.  Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[121]  G Nilsson,et al.  Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. , 1999, Cancer research.

[122]  B. Bhavnani,et al.  Discordant expression of insulin-like growth factors and their receptor messenger ribonucleic acids in endometrial carcinomas relative to normal endometrium , 1999, Molecular and Cellular Endocrinology.

[123]  J. Swantek,et al.  Prolonged activation of ERK2 by epidermal growth factor and other growth factors requires a functional insulin-like growth factor 1 receptor. , 1999, Endocrinology.

[124]  D. Leroith,et al.  Normal growth and development in the absence of hepatic insulin-like growth factor I. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[125]  T. Quattrin,et al.  Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group. , 1999, Diabetes care.

[126]  M. Spitz,et al.  Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. , 1999, Journal of the National Cancer Institute.

[127]  W. Lopaczynski.  Differential regulation of signaling pathways for insulin and insulin-like growth factor I. , 1999, Acta biochimica Polonica.

[128]  G Bartsch,et al.  Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. , 1999, Cancer research.

[129]  P. Lollini,et al.  Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. , 1998, Cancer research.

[130]  P. Leigh,et al.  A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis , 1998, Neurology.

[131]  K. Takano,et al.  Serum high molecular weight form of insulin-like growth factor II from patients with non-islet cell tumor hypoglycemia is O-glycosylated. , 1998, The Journal of clinical endocrinology and metabolism.

[132]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[133]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[134]  Y. Nikiforov,et al.  Overexpression of Insulin-Like Growth Factor-Binding Protein-4 (IGFBP-4) in Smooth Muscle Cells of Transgenic Mice through a Smooth Muscle α-Actin-IGFBP-4 Fusion Gene Induces Smooth Muscle Hypoplasia. , 1998, Endocrinology.

[135]  M. Weiss,et al.  Mini-proinsulin and mini-IGF-I: homologous protein sequences encoding non-homologous structures. , 1998, Journal of molecular biology.

[136]  M. Gaweł,et al.  Effect of recombinant human insulin-like growth factor-I on progression of ALS , 1997, Neurology.

[137]  J. French,et al.  Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. , 1997, Cancer research.

[138]  A. Hoffman,et al.  Decreased expression of Wilms' tumor gene WT-1 and elevated expression of insulin growth factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. , 1997, The Journal of clinical endocrinology and metabolism.

[139]  C. Christoffersen,et al.  Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor , 1997, Diabetologia.

[140]  L. Slieker,et al.  Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor , 1997, Diabetologia.

[141]  J. Eckel,et al.  Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells. , 1997, European journal of pharmacology.

[142]  A. Klibanski,et al.  Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. , 1996, The Journal of clinical endocrinology and metabolism.

[143]  A. D'ercole.  Insulin-like growth factors and their receptors in growth. , 1996, Endocrinology and metabolism clinics of North America.

[144]  James M. Roberts,et al.  Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle , 1996, Science.

[145]  A. Moses,et al.  Recombinant Human Insulin-Like Growth Factor I Increases Insulin Sensitivity and Improves Glycemic Control in Type II Diabetes , 1996, Diabetes.

[146]  T. Moody,et al.  Monoclonal antibody αIR‐3 inhibits non‐small cell lung cancer growth in vitro and in vivo , 1996 .

[147]  D. Matthews,et al.  Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy--a clinical research center study. , 1995, The Journal of clinical endocrinology and metabolism.

[148]  B. Ursø,et al.  Role of the time factor in signaling specificity: application to mitogenic and metabolic signaling by the insulin and insulin-like growth factor-I receptor tyrosine kinases. , 1995, Metabolism: clinical and experimental.

[149]  R. Baserga,et al.  Stabile D‐peptide analog of insulin‐like growth factor‐l inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[150]  K. Bornfeldt,et al.  The insulin-like growth factor system in vascular smooth muscle: interaction with insulin and growth factors. , 1995, Metabolism: clinical and experimental.

[151]  R. Baserga,et al.  Different Effects on Mitogenesis and Transformation of a Mutation at Tyrosine 1251 of the Insulin-like Growth Factor I Receptor (*) , 1995, The Journal of Biological Chemistry.

[152]  C. Lang,et al.  Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. , 1995, The Journal of clinical endocrinology and metabolism.

[153]  A. Ferber,et al.  Insulin‐like growth factor I receptor is required for the mitogenic and transforming activities of the platelet‐derived growth factor receptor , 1995, Journal of cellular physiology.

[154]  B. Beaufrère,et al.  Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect. , 1995, The Journal of clinical endocrinology and metabolism.

[155]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[156]  L. Helman,et al.  In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. , 1994, Cancer research.

[157]  D. Coppola,et al.  Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts , 1994, Molecular and cellular biology.

[158]  C. Pepine,et al.  Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? , 1994, Circulation.

[159]  J. Baker,et al.  Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r) , 1993, Cell.

[160]  K. Alberti,et al.  A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. , 1993, The Journal of clinical investigation.

[161]  S. Nagataki,et al.  Trial of Insulinlike Growth Factor I Therapy for Patients With Extreme Insulin Resistance Syndromes , 1993, Diabetes.

[162]  Martina,et al.  Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. , 1992, The Journal of clinical investigation.

[163]  A. Chambers,et al.  Differences in the repertoires of basement membrane degrading enzymes in two carcinoma sublines with distinct patterns of site-selective metastasis. , 1992, Biochimica et biophysica acta.

[164]  M. Fishbein,et al.  Effects of hypophysectomy on vascular insulin-like growth factor-I gene expression after balloon denudation in rats. , 1992, Atherosclerosis.

[165]  H. Häring,et al.  An altered IGF-I receptor is present in human leukemic cells. , 1990, The Journal of biological chemistry.

[166]  R. Humbel,et al.  Insulin-like growth factors I and II. , 1990, European journal of biochemistry.

[167]  M. Fishbein,et al.  Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. , 1990, Circulation research.

[168]  R. Baxter,et al.  Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. , 1990, The Journal of clinical endocrinology and metabolism.

[169]  W. Rutter,et al.  Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation , 1990, Molecular and cellular biology.

[170]  太田 明.  Insulin-like growth factor I receptors on mouse neuroblastoma cells : two β subunits are derived from differences in glycosylation , 1990 .

[171]  C. Osborne,et al.  Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. , 1989, The Journal of clinical investigation.

[172]  M. Schalling,et al.  Induction of insulin-like growth factor I messenger ribonucleic acid during regeneration of rat skeletal muscle. , 1989, Endocrinology.

[173]  P. Rotwein,et al.  Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. , 1989, Endocrine reviews.

[174]  D. Clemmons,et al.  Radioimmunoassay of a 26,000-dalton plasma insulin-like growth factor-binding protein: control by nutritional variables. , 1988, The Journal of clinical endocrinology and metabolism.

[175]  D. Leroith,et al.  Insulin-like growth factor I receptors on mouse neuroblastoma cells. Two beta subunits are derived from differences in glycosylation. , 1988, European journal of biochemistry.

[176]  L. Mathews,et al.  Regulation of insulin-like growth factor messenger ribonucleic acid in rat growth plate by growth hormone. , 1988, Endocrinology.

[177]  S. Gammeltoft,et al.  Expression of two types of receptor for insulin-like growth factors in human malignant glioma. , 1988, Cancer research.

[178]  D. Clemmons,et al.  6 Factors controlling blood concentration of somatomedin C , 1984 .

[179]  D. Clemmons,et al.  Factors controlling blood concentration of somatomedin C. , 1984, Clinics in endocrinology and metabolism.

[180]  E. Froesch,et al.  Insulin-like growth factors in the fed and fasted states. , 1982, The Journal of clinical endocrinology and metabolism.